Cumberland Pharmaceuticals Inc. CPIX Cash Flow

Cumberland pharmaceuticals inc. (CPIX)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net income (loss)
-4,571	-3,546	-4,811	-4,508	-4,687	-7,038	-5,623	-4,716	-9,148	-8,049	-7,997	-7,145	-2,028	-1,003	-105	-79	376	671	1,191	1,798	2,113	2,362	202	-1,359	-2,717	-2,151	1,153	3,848	6,233	5,806	4,920	4,897	5,329	5,626	0	0	0
Discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) from continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:
Depreciation and amortization expense
4,479	4,404	4,153	3,762	3,365	2,982	2,781	2,728	2,679	2,647	2,586	2,539	2,476	2,396	2,353	2,275	2,267	2,246	2,283	2,332	2,155	1,989	1,768	1,492	1,406	1,301	1,154	1,070	974	901	903	954	995	1,040	0	0	0
Deferred tax expense
21	65	125	125	125	81	-87	-87	3,448	4,206	4,250	4,380	1,173	619	1,108	999	694	490	0	0	0	-	-	-	-	-1,579	-906	-764	-764	-829	0	0	0	-	-	-	-
Share-based compensation
1,386	1,485	1,467	1,460	1,389	1,364	1,271	1,229	1,199	1,115	1,077	995	931	852	819	481	550	622	646	985	882	761	736	695	672	674	560	550	550	636	0	0	0	-	-	-	-
Stock-based compensation - nonemployees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Stock-based compensation - employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Decrease in non-cash contingent consideration
273	0	763	403	351	81	0	0	-1	91	-28	-100	-505	-1,026	-1,286	-1,057	-355	90	1,046	1,255	1,483	1,653	1,637	744	-242	48	1,072	2,921	4,048	3,760	1,874	1,693	2,405	2,355	0	0	0
Noncash interest expense
48	47	92	94	92	99	61	60	69	77	84	98	97	84	74	63	52	46	59	46	40	38	24	24	24	24	20	24	24	24	22	25	119	137	0	0	0
Noncash investment gains
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Net changes in assets and liabilities affecting operating activities:
Accounts receivable
-1,438	1,937	241	2,621	2,904	-550	-150	-300	-3,424	1,064	533	1,555	4,902	1,253	873	-1,257	-352	572	502	-206	-242	974	1,101	2,043	-550	-1,486	-1,273	-1,020	1,504	-1,065	962	171	-682	1,937	0	0	0
Inventories
-3,072	-2,860	-2,363	-2,497	-878	-460	568	1,791	1,564	1,366	874	632	1,022	1,101	777	126	-560	-1,330	-1,924	-2,201	-2,788	-1,532	-714	-507	20	-495	-2,076	-1,222	-13	443	637	-136	-1,817	-1,909	0	0	0
Other current assets and other assets
-371	587	59	-48	-245	-712	-320	188	340	1,074	743	1,539	1,154	1,556	1,264	783	928	263	-103	-113	561	1,011	1,060	644	194	-117	-401	415	332	648	0	0	0	-	-	-	-
Other current assets and other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accounts payable and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,296	0	0	0
Accounts payable and other current liabilities
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Other long-term liabilities
-1,241	-729	-509	-638	-617	-159	315	309	424	413	358	490	401	386	203	54	20	-2	118	132	192	162	180	259	167	187	824	691	-75	56	0	0	0	-	-	-	-
Net cash provided by (used in) operating activities from continuing operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by (used in) operating activities
4,330	3,056	5,922	3,547	2,491	3,112	-1,070	1,562	-1,761	-557	721	22	1,410	569	1,073	1,265	4,441	5,876	7,289	8,942	7,744	6,693	3,765	772	58	746	2,926	5,682	6,195	7,135	6,177	7,032	10,348	8,722	0	0	0
Cash flows from investing activities:
Additions to property and equipment
241	246	450	412	388	455	274	264	246	275	205	203	181	130	144	151	107	142	109	177	242	163	155	76	66	97	263	355	493	464	309	330	256	257	0	0	0
Purchases of marketable securities
3,928	11,745	8,347	12,282	12,236	19,572	21,201	18,094	16,738	2,379	3,858	3,715	5,099	5,473	5,971	6,441	7,194	7,528	5,653	4,998	4,957	4,207	3,754	3,254	2,151	4,371	7,382	7,875	8,837	21,860	0	0	0	-	-	-	-
Proceeds from sale of marketable securities
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Cash paid for acquisitions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Additions to intangible assets
957	772	2,905	3,621	3,650	3,819	1,783	1,052	1,292	1,213	1,287	1,676	1,829	2,000	1,718	894	1,119	2,556	3,876	5,109	4,775	3,101	6,479	6,364	6,889	7,462	3,051	3,381	2,852	2,071	1,661	653	340	180	0	0	0
Net cash used in investing activities
3,450	2,297	-21,017	-23,534	-17,926	-27,724	-3,401	-1,612	-1,580	9,512	5,105	-1,629	-2,591	-3,115	-1,958	-1,389	-2,124	-2,344	-3,519	-4,319	-5,135	-6,034	-4,288	-4,051	-3,839	-5,071	-4,107	-5,056	-6,275	-19,177	-20,430	-19,195	-16,589	-437	0	0	0
Cash flows from financing activities:
Borrowings on line of credit
75,500	76,000	76,000	68,000	63,000	56,000	45,800	41,800	36,500	24,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-500	0	0	0	-	-	-	-
Repayments on line of credit
77,000	77,500	68,000	60,000	55,000	45,800	41,800	36,500	28,600	18,800	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,333	0	0	0
Proceeds from sales of common stock, net of offering costs
-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of deferred equity offering costs
-	-	-	-	-	383	276	276	276	27	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of shares of common stock, net of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	21	21	12	0	0	0	0	-41	-3	31	31	618	528	651	742	629	0	0	0
Cash payment of contingent consideration
786	1,033	908	684	507	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of subsidiary shares from noncontrolling interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of common shares
3,224	3,494	3,090	2,148	2,576	2,879	3,213	3,884	4,194	3,724	3,535	2,622	2,087	2,520	2,548	3,671	4,606	5,338	6,246	6,091	5,107	4,315	3,621	3,218	3,777	4,800	5,178	7,686	7,682	8,086	8,189	6,257	5,821	4,247	0	0	0
Excess tax (expense) benefit derived from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,026	-1,286	-1,057	-355	90	1,046	1,255	1,483	1,653	1,637	744	-242	48	1,072	2,921	4,048	3,760	1,874	1,693	2,405	2,355	0	0	0
Net cash used in financing activities
-5,363	-5,080	3,813	5,031	4,781	7,138	711	1,339	3,630	1,947	645	386	-285	-1,147	-1,884	-2,978	-4,920	-5,194	-5,097	-4,733	-2,612	-1,662	-5,844	-7,334	-8,380	-9,154	-3,609	-3,234	-4,353	-4,207	-6,020	-5,395	-4,074	-3,579	0	0	0
Net decrease in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	0	0	288	-	6,472	-1,221	-1,466	-3,692	-2,770	-3,103	-2,603	-1,662	-1,327	-110	-3	-1,003	-6,367	-10,613	-12,161	-13,479	-4,790	-2,608	-4,434	-16,249	-20,273	-17,558	-10,315	4,705	0	0	0
Supplemental non-cash operating, investing and financing activities:
Noncash investing and financing activities:
Recognition of operating lease assets and liabilities through adoption of ASC 842
0	3,629	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in unpaid additions to intangibles, property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Change in unpaid fixed asset additions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0